Navigation Links
Royalty Pharma Announces Proposal To Acquire Elan
Date:2/25/2013

"considered", "likely", and variations of these words and similar future or conditional expressions are intended to identify forward looking statements but are not the exclusive means of identifying such statements. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur.

Examples of such forward looking statements include, but are not limited to, statements about expected benefits and risks associated with the Possible Offer; projections or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, Royalty Pharma or the combined company following the Possible Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, Royalty Pharma or the combined company following the Possible Offer; statements concerning any future Irish, U.S. or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological developments in the financial services industry; and statements of assumptions underlying such statements.

Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.

No Profit ForecastNo statement in this announcement is intended to constitute a profit forecast for any period, nor should any statement be interpreted to mean that earnings or earn
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Royalty Rates Take Center Stage in Biopharma Dealmaking
2. Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Response to Citizens Petition
3. Health Outcomes Liaisons (HOLs) Serve as Key Bridge between Pharmaceutical Sector and Managed Care Groups
4. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
5. State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride
6. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
7. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
8. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
9. Promise and Problems Signal Mixed Year Ahead for Biopharmaceutical Industry, Says Pharmaceutical Executive Magazine
10. Webcast Alert: Isis Pharmaceuticals 2012 Financial Results and Highlights Conference Call
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... SINGAPORE , Sept. 15, 2014  Catalist-listed QT ... "the Group"), a developer and manufacturer of minimally invasive ... pleased to announce that the Group has enrolled the ... Germany . Multiple patients have already been ... , at Auckland City Hospital, in Auckland, ...
(Date:9/15/2014)... Sept. 15, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... paid the September 12, 2014, regular quarterly dividend payment of ... PDL as of September 5, 2014, the record date. ... manages a portfolio of patents and royalty assets, consisting ... and license agreements with various biotechnology and pharmaceutical companies. ...
(Date:9/15/2014)... , Sept. 15, 2014 Research and ... "Closed Drug Transfer Systems to 2020" report to ... deemed hazardous to humans has been receiving increasing amounts ... these substances become more clearly understood. For caregivers and ... forefront of attempts to mitigate exposure to cytotoxic drugs ...
Breaking Medicine Technology:First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3
... Doubled Time to Progression and Overall Response Rate as ... in Patients with 2nd or 3rd Line Metastatic Colon ... KERX ) today announced data on the ... cancer, in combination with capecitabine as a treatment for ...
... increase the risk of breast cancer recurrence , ... found that taking tamoxifen with certain antidepressants more than ... taking both medications. The antidepressants inhibit an enzyme, CYP2D6, ... ) , , The study ...
Cached Medicine Technology:Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6New Research Shows Antidepressants May Thwart Breast Cancer Treatment 2New Research Shows Antidepressants May Thwart Breast Cancer Treatment 3
(Date:9/15/2014)... one out of every 40 individuals in the United States ... atrophy (SMA), a neurodegenerative disease that causes muscles to weaken ... made a recent breakthrough with the development of a new ... the disease. In April, a patent was filed for the ... is using to fight SMA is to ,repress the repressor," ...
(Date:9/15/2014)... September 15, 2014 In order to ... medicine often act conjointly to quantify, define and model ... become an integral part of medical care. , The ... the studies conducted by the non-profit Institute of BioAcoustic ... demonstrated that math can be much more than a ...
(Date:9/15/2014)... Dennis Thompson ... News) -- The severe respiratory virus believed to have ... states has now spread to the Northeast, health officials ... confirmed on Friday more than a dozen cases of ... for children with asthma. And on Saturday, the ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 As ... end of its first full year, there are ... maturing; especially in the evolution of its marketing ... approach being taken by Denver's Kindman, one of ... and distributors. , Kindman has pioneered the first-ever ...
(Date:9/15/2014)... September 15, 2014 As Risperdal lawsuits ... Bernstein Liebhard LLP notes that a new study has ... curbing aggression in children with ADHD when it is ... in behavioral management techniques. According to a report from ... and aggression problems, half of whom took Concerta, a ...
Breaking Medicine News(10 mins):Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4
... 2008) University of Minnesota researchers have created a beating ... called whole organ decellularization, scientists from the University of Minnesota ... dead rat and pig hearts and reseeding them with a ... in the January 13 issue of Nature Medicine., The ...
... injected into ,skeleton, of animal organ was beating in ... -- An organ-building biotechnology that could create transplantable hearts ... important laboratory tests, researchers report. , The technique, called ... heart tissue, according to a report in the Jan. ...
... here today," says James, a ClearChoices speaker. "I was,addicted ... I was at dinner each,night... they thought everything was ... and prevent them from going through what I went ... Chrysler LLC and,Barrett- Jackson will allow notMYkid to educate ...
... 500 Executive Driving Global Breast Cancer Leader,s Promise ... End Breast Cancer Forever, ATLANTA, Jan. 12 Hala ... the global leader in the fight to end breast,cancer forever, ... annual Trumpet Awards event in Atlanta with a ,High Heels ...
... LAUDERDALE, Fla., Jan. 11 eDiets.com,Inc. (Nasdaq: DIET ... Hamilton. Mr. Hamilton, who joined the Company in November,1999, ... privately held,company. Mr. Hamilton will remain available to assist ... firm to find a replacement and has,appointed Carla Cox, ...
... CHAPEL HILL, N.C., Jan. 11 Today,s top-level,pharmaceutical ... the,team that will carry out the plan as ... study by pharmaceutical research firm, Best,Practices, LLC., ... looking to invest people and money earlier in ...
Cached Medicine News:Health News:U of M researchers create beating heart in laboratory 2Health News:Biotechnology Builds a New Heart 2Health News:Biotechnology Builds a New Heart 3Health News:First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 2Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 3Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2
... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
... Tissue Anchor 2 mm is a resorbable repair ... using sutures. The resorbable repair device is implanted ... is used to reattach damaged soft tissue. The ... derived from glycolide and lactide colored with D&C ...
... of anchor is generally used when ... This 2.9mm anchor is packaged sterile ... or 2-0) and needles. Although pre-drilling ... the Mini Harpoon®, 1.6mm & 1.8mm ...
The MINI-TAG™ instrument systems are indicated for ulnar collateral ligament repair, scapholunate dissolution, flexor avulsions, and carpometa-carpal arthroplasty....
Medicine Products: